How to Benchmark Your Cancer Biomarker for the Clinic
Tuesday, 18 May 2021
||14:00 - 16:00
||Moderators: Laura Bell & Janine Lupo
Session Number: MIS-12
Parent Session: How to Benchmark Your Cancer Biomarker for the Clinic
Laura Bell, Janine Lupo
This Symposium was proposed by the MR of Cancer study group. Clinical biomarkers are an important component of cancer diagnosis, the determination of treatment, and response assessment for improved patient care. In this proposed symposium, the MR Cancer study group aims to outline the complete process of benchmarking cancer biomarkers for widespread clinical adoption. Before translating quantitative imaging biomarkers into clinical trials, it is vital to standardize and evaluate their performance under diverse conditions in order to determine clinical readiness at distinct junctures in the course of their development. For this symposium, we have invited 5 speakers to give 20-minute talks on their personal experiences in developing and benchmarking clinical biomarkers. The first talk will start with an overview of the importance and the multiple stages of benchmarking. The remaining presentations will each focus on a phase of the benchmarking process: basic benchmarking (evaluating systematic variations using phantoms and healthy volunteers), benchmarking for novel MR sequences, benchmarking for software analysis tools, and finally the success of biomarkers out of clinical trials and into clinical practice.
Cancer imaging researchers who are interested in translating novel methodologies, biomarkers, and image analysis tools into the clinic.
As a result of attending this course, participants should be able to:
Upon completion of this course, participants should be able to: - Describe the spectrum of benchmarking from initial experiments in animals and phantoms to routine clinical use; - Identify the systematic challenges associated with benchmarking and ongoing standardization efforts to minimize variation; and - Explain the validation process for a biomarker and image processing tool to become approved for routine clinical use and give an example of each.
||Overview of Benchmarking for Clinical Translation: From Technique Development to Clinical Tool
American College of Radiology
||Benchmarking: Back to Basics
National Institute of Standards & Technology
||Technical Benchmarking & Standardization of Novel Diffusion-Based Biomarker Technologies
University of Michigan
||Technical Benchmarking for Image Analysis/Prediction Tools
Massachusetts General Hospital, Harvard Medical School
||From Clinical Trials to Clinical Use: Neuro-Oncologic Imaging
University of California, Los Angeles